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oninvasive Home Telemonitoring
or Patients With Heart Failure at
igh Risk of Recurrent Admission and Death
he Trans-European Network–Home-Care
anagement System (TEN-HMS) Study
ohn G. F. Cleland, MD,* Amala A. Louis, MD,* Alan S. Rigby, PHD,* Uwe Janssens, MD,†
ggie H. M. M. Balk, MD,‡ on behalf of the TEN-HMS Investigators
ingston Upon Hull, United Kingdom; Aachen, Germany; and Rotterdam, the Netherlands
OBJECTIVES We sought to identify whether home telemonitoring (HTM) improves outcomes compared
with nurse telephone support (NTS) and usual care (UC) for patients with heart failure who
are at high risk of hospitalization or death.
BACKGROUND Heart failure is associated with a high rate of hospitalization and poor prognosis. Telemoni-
toring could help implement and maintain effective therapy and detect worsening heart failure
and its cause promptly to prevent medical crises.
METHODS Patients with a recent admission for heart failure and left ventricular ejection fraction (LVEF)
40% were assigned randomly to HTM, NTS, or UC in a 2:2:1 ratio. HTM consisted of
twice-daily patient self-measurement of weight, blood pressure, heart rate, and rhythm with
automated devices linked to a cardiology center. The NTS consisted of specialist nurses who
were available to patients by telephone. Primary care physicians delivered UC. The primary
end point was days dead or hospitalized with NTS versus HTM at 240 days.
RESULTS Of 426 patients randomly assigned, 48% were aged 70 years, mean LVEF was 25% (SD,
8) and median plasma N-terminal pro-brain natriuretic peptide was 3,070 pg/ml (interquar-
tile range 1,285 to 6,749 pg/ml). During 240 days of follow-up, 19.5%, 15.9%, and 12.7% of
days were lost as the result of death or hospitalization for UC, NTS, and HTM, respectively
(no significant difference). The number of admissions and mortality were similar among
patients randomly assigned to NTS or HTM, but the mean duration of admissions was
reduced by 6 days (95% confidence interval 1 to 11) with HTM. Patients randomly assigned
to receive UC had higher one-year mortality (45%) than patients assigned to receive NTS
(27%) or HTM (29%) (p  0.032).
CONCLUSIONS Further investigation and refinement of the application of HTM are warranted because it may
be a valuable role for the management of selected patients with heart failure. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.050Cardiol 2005;45:1654–64) © 2005 by the American College of Cardiology Foundation
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lpidemiologic studies suggest that one in six members of
he population will develop heart failure (1,2). Heart failure
s one of the most common medical reasons for admission to
he hospital and has a three-year mortality rate of approx-
See page 1665
mately 60% (3,4). After a person is admitted to the hospital
ith heart failure, there is a one in four chance of that
atient’s rehospitalization or death within 12 weeks (5).
From the *University of Hull, Kingston Upon Hull, United Kingdom; †Univer-
itätsklinikum, Aachen, Germany; and ‡Thoraxcenter, Erasmus MC, Rotterdam, the
etherlands. The study was funded jointly by the European Union’s Trans European
etwork (TEN) Telecom programme, which provided most of the financial support
or clinical investigators, data collection, and analysis, and by Philips Medical
ystems, which provided information technology systems, telemonitoring solutions,
nd support engineers and contributed to investigator-site staff costs. The authors had
irect access to the independent study statistician.m
Manuscript received April 22, 2004; revised manuscript received January 7, 2005,
ccepted January 11, 2005.Effective treatment is available for heart failure due to left
entricular (LV) systolic dysfunction (6). Unfortunately,
ecause of inadequate organization of care, effective phar-
acologic treatment often is not given and, when it is, often
t doses lower than those shown to be effective (5,7). There
s growing evidence that improved organization of heart
ailure care, as for other malignant diseases, can have a
ajor impact on hospitalization and/or death (8–12). How-
ver, relative to the number of patients affected, there is a
ack of healthcare staff able to provide expert management
or heart failure. Novel methods for the delivery of quality
ealthcare could increase the effectiveness of management
hile containing costs and using scarce human resources to
aximum effect.
Interest in telemedicine as a way of providing care has
een stimulated by the rising costs of hospital treatment,
apid advances in technology, and the wider availability of
ow-cost, patient-friendly equipment (13,14). Home tele-onitoring (HTM) allows the evaluation of patients’ vital
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May 17, 2005:1654–64 The TEN-HMS Studyigns once or more per day and provides diagnostic infor-
ation that can be transmitted to health professionals. It
as the potential to involve patients more in their own care,
ssist the titration of medications, improve compliance, and
elp providers identify early signs of worsening heart failure
nd its precipitating factors. Home telemonitoring also may
ssist with care at home or early discharge planning, thereby
educing admissions, hospital days, and rates of mortality.
he purpose of the Trans-European Network–Home-Care
anagement System (TENS-HMS) study was to address
ome of these issues.
ETHODS
enters and patients. Hospitals that did not already have
comprehensive heart failure management organization in
lace were selected, although most had one or more spe-
ialist nurses and doctors interested in the management of
eart failure. Twelve main and four satellite hospitals in
ermany, the Netherlands, and the United Kingdom were
dentified. Each hospital provided a secondary care function
o their local community from which patients were
ecruited.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
HTM  home telemonitoring
LV  left ventricular
NT-proBNP  N-terminal pro-brain natriuretic peptide
NTS  nurse telephone support
NYHA  New York Heart Association
TEN-HMS  The Trans-European Network–
Home-Care Management System
UC  usual care
WHARF  Weight Monitoring in Heart FailureFigure 1. Diagrammatic representation of the telemonitorinPatients who were ready for or recently discharged after
n admission for worsening heart failure were evaluated for
nclusion provided their primary care physician agreed. To
e included, patients had to have a hospital admission due
o or complicated by worsening heart failure lasting 48 h
ithin the last six weeks; to have persisting symptoms of
eart failure, a LV ejection fraction 40%, an LV end-
iastolic dimension 30 mm/m (height); and to be receiv-
ng furosemide at a dose 40 mg/day or equivalent (e.g.,
1 mg of bumetanide or 10 mg of torasemide). In
ddition to these criteria, patients had to have at least one of
he following markers of a further increase in risk: an
nplanned cardiovascular admission lasting 48 h within
he previous 2 years, an LV ejection fraction 25%, or
reatment with furosemide at a dose of 100 mg/day or
quivalent. Patients who were younger than 18 years of age;
ho were deemed unable to comply with home telemoni-
oring; or who were awaiting revascularization, cardiac
esynchronization, or heart transplantation were excluded.
he study adhered to local and international guidelines for
ood clinical practice and was approved by relevant ethical
ommittees for each participating hospital. Written in-
ormed consent was obtained from all patients.
ethods. Baseline demographic and social details, clinical
istory, medication, New York Heart Association (NYHA)
unctional classification, weight, and physical signs were
ecorded, and a blood sample was taken for the measure-
ent of hemoglobin, electrolytes, urea, creatinine, and
-terminal pro-brain natriuretic peptide (NT-proBNP;
oche Elecsys proBNP assay, Mannheim, Germany).
Patients were then assigned randomly to receive HTM,
urse telephone support (NTS), or usual care (UC). The
ain comparison of interest was that between NTS and
TM and, accordingly, twice as many patients were as-g system used in the trial. ECG  electrocardiogram.
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The TEN-HMS Study May 17, 2005:1654–64igned randomly to these groups. The UC group was used
s a reference to ascertain whether either HTM or NTS had
hanged outcome.
After acquiring consent, patients’ baseline data were
ecorded and sent to an independent statistical group (i.e.,
nstitute for Medical Informatics and Biostatistics, Basel).
andom permuted blocks for each center were used to
llocate patients to treatment groups. The block size was
ept confidential and was varied to avoid investigators
redicting which management-group would be the next to
e allocated.
All patients were given an individualized written man-
gement plan by the investigator that described what
harmacologic treatment they should receive, in what order,
nd how it should be monitored. All patients required a loop
iuretic according to the study entry criteria. The manage-
ent plan focused on treatment of LV systolic dysfunction
ith appropriate doses of angiotensin-converting enzyme
ACE) inhibitors and beta-blockers and, if severe symptoms
ersisted, spironolactone according to regional guidelines
15). Digoxin and anticoagulants were recommended for
atients in atrial fibrillation. Patients who could not tolerate
r who had contraindications to the aforementioned med-
cation were permitted in the study provided an explanation
as given.
For patients assigned randomly to UC, the patient
anagement plan was sent to the patient’s primary care
hysician, who was asked to implement it. Where the usual
rganization of care involved nurse specialist titration of
rugs, this was allowed. Patients were assessed at a research
linic every four months to assess intervening history,
Figure 2. Consort diagram showing distymptoms and signs, renal function, and serum electrolytes.
ontact with the research team was discouraged between
isits.
Patients assigned randomly to receive NTS also were
anaged as described for UC except they were contacted by
elephone each month by a heart failure specialist nurse to
ssess their symptoms and current medication. The nurse
ould proffer advice to the patient at this time and provide
eedback to the primary care provider. Patients also were
old that they could contact the study nurse by telephone at
ny time, either directly or by leaving a message on a
elephone-answering machine. However, should an out-of-
ours emergency arise, they were told to contact their
rimary care doctor or the ambulance service.
Patients assigned randomly to HTM received instruc-
ions on how to use the telemonitoring equipment, and
urse telephone support was offered as for the NTS group.
s soon as possible after randomization (median 12 days;
pper quartile 24 days), a service engineer visited the
atient’s home to install the equipment, which consisted of
ow-profile, electronic, weighing scales, an automated
phygmomanometer, and a single-lead electrocardiogram
sing wrist-band electrodes (Fig. 1). Each device contained
short-range radio-transmitter that allowed it to commu-
icate automatically with a hub connected to the patient’s
onventional telephone line and, thereby, automatically to a
entral web server and then via secure Intranet connections
o a workstation at each investigator site. Data were en-
rypted during transmission to ensure patient confidential-
ty. Patients were asked to make a set of measurements every
ay before breakfast and before their evening meal, after
on, follow-up, and outcome of patients.ributi
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May 17, 2005:1654–64 The TEN-HMS Studyable 1. Baseline Characteristics
Variable Usual Care Nurse Telephone Support Home Telemonitoring
umber randomly assigned 85 173 168
ean age, yrs (SD) 68 (10) 67 (11) 67 (13)
patients age 70 yrs 49 47 54
omen (%) 18 28 20
ives alone 22 (26%) 49 (28%) 40 (24%)
ives with partner or friend 62 (73%) 123 (71%) 128 (76%)
rimary cause of heart failure
Coronary disease 58 (68%) 94 (54%) 102 (61%)
Hypertension 4 (5%) 16 (9%) 7 (4%)
Idiopathic dilated cardiomyopathy 14 (17%) 37 (21%) 44 (26%)
Alcohol-related 3 (4%) 5 (3%) 3 (2%)
Valve-related 4 (5%) 16 (9%) 8 (5%)
Other 2 (2%) 4 (2%) 4 (2%)
omorbidities
Previous myocardial infarction 57 (67%) 90 (52%) 94 (56%)
Valve disease/mitral regurgitation 31 (36%)/28 (33%) 61 (35%)/52 (30%) 64 (38%)/58 (35%)
Chronic or paroxysmal atrial fibrillation 33 (39%) 80 (46%) 79 (47%)
Hypertension 34 (40%) 92 (53%) 74 (44%)
Stroke, any 7 (8%) 17 (10%) 15 (9%)
Chronic lung disease 25 (29%) 38 (22%) 40 (24%)
Diabetes, any 30 (35%) 60 (35%) 59 (35%)
Systolic blood pressure (mm Hg) 115 (19) 116 (21) 112 (18)
Diastolic blood pressure (mm Hg) 69 (12) 69 (11) 69 (11)
Weight (kg) 79.9 (17.2) 74.9 (16.1) 76.9 (17.1)
Body mass index 27.0 (5.0) 25.8 (4.5) 26.1 (4.9)
nvestigations
Hemoglobin (g/dl) 13.2 (1.9) 13.3 (2.4) 13.0 (1.9)
Serum sodium (mmol/l) 137 (4) 138 (5) 137 (5)
Serum creatinine (mol/l) 140 (50) 136 (56) 133 (50)
Mean LVEF (%) 24 (8) 25 (8) 25 (8)
% with LVEF 25% 57 50 48
NT proBNP (pg/ml), median [IQR] 2,309 [1,057 to 6,935] 2,909 [1,116 to 6,140] 3,873 [1,607 to 7,518]
Mean dose of furosemide or equivalent, mg (SD) 104 (92) 112 (85) 112 (93)
RQ  interquartile range; LVEF  left ventricular ejection fraction.able 2. NYHA Functional Class Before and After Randomization
Worst State in Last Month At Randomization 120-Day Follow-Up* 240-Day Follow-Up*
sual care
NYHA I 5 (6%) 14 (18%) 14 (18%) 13 (17%)
NYHA II 10 (13%) 28 (36%) 27 (35%) 20 (26%)
NYHA III 23 (30%) 33 (42%) 16 (21%) 15 (19%)
NYHA IV 40 (51%) 3 (4%) 4 (5%) 8 (10%)
Dead 17 (22%) 22 (28%)
urse telephone support
NYHA I 4 (3%) 28 (18%) 34 (21%) 40 (25%)
NYHA II 23 (15%) 70 (44%) 62 (39%) 47 (30%)
NYHA III 35 (22%) 47 (30%) 33 (21%) 34 (21%)
NYHA IV 97 (61%) 14 (9%) 9 (6%) 7 (4%)
Dead 21 (13%) 31 (19%)
ome telemonitoring
NYHA I 7 (5%) 34 (22%) 35 (23%) 36 (24%)
NYHA II 24 (16%) 71 (46%) 71 (46%) 53 (35%)
NYHA III 28 (18%) 35 (23%) 27 (18%) 27 (18%)
NYHA IV 94 (61%) 13 (8%) 5 (3%) 9 (6%)
Dead 15 (10%) 28 (17%)
report on NYHA functional class was missing at one or more time points in 7 patients randomly assigned to usual care, 14 patients to nurse telephone support, and 15 patients
o home telemonitoring. Percentages shown are percentage of those in whom data on NYHA were adequately reported. *Data for evaluation closest to 120 and 240 days were
sed; hence, numbers of deaths differ slightly from those shown in Table 4, in which the data for 240 days precisely are shown.
NYHA  New York Heart Association.
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The TEN-HMS Study May 17, 2005:1654–64mptying their bladders, while wearing light clothing, no
hoes, and before the next dose of medication. Thus, the
atient’s weight, blood pressure, heart rate, and rhythm
ere monitored twice daily. Values greater than or less than
reset limits were notified automatically to the study nurses,
ho then reviewed the information and took action either
irectly for any short-term advice or through the primary
are physician if long-term changes in therapy were re-
uired. Nurses also could scan patient data manually to
dentify any trends that they considered as requiring action.
tudy personnel were primarily responsible for implemen-
ation of the management plan in patients assigned ran-
omly to HTM. The primary care physician and the
nvestigator were kept informed of all contacts.
Guidelines for the management of a number of common
cenarios, depending on the stability of the patients’ symp-
oms and current treatment, were developed by the steering
roup. A weight change of 2 kg, a resting heart rate 50
eats/min or 80 beats/min, new-onset sustained arrhyth-
ia, or a systolic blood pressure 90 mm Hg or 140 mm
g were considered an indication for close review of the
atient’s management. During titration of beta-blockers, a
eart rate 65 beats/min was an indication to delay further
ncreases in dose.
utcome measures. The primary outcome was days lost
ecause of death or hospitalization in acute medical/surgical
eds for any reason during 450 days, and the primary
omparison of interest was between patients assigned ran-
omly to NTS and HTM. The assumption was that the
rimary effect of HTM, compared with NTS, would be to
able 3. Medication Use According to the Patient’s Managemen
U
n
Treated
eaths N/A
atients alive and with available management plan 81
CE inhibitors and ARBs
Intention to treat with ACE inhibitor 67
Actually receiving ACE inhibitor
(and % intended by PMP)
61
Intention to treat with ARB inhibitor 12
Actually receiving ARB
(and % intended by PMP)
6
eta-blockers
Intention to treat with beta-blocker 57
Actually receiving beta-blocker
(and % intended by PMP)
44
pironolactone
Intention to treat with spironolactone 50
Actually receiving spironolactone
(and % intended by PMP)
37
p  0.0002 for HTM vs. NTS; †p  0.0166 for HTM vs. UC (p  0.0014 for ch
s. UC (p  0.0040 for chi-squared in 3-way comparison); p  0.0097 for HTM v
20 and 240 days were used, hence numbers of deaths differ slightly from those sho
ACE angiotensin-converting enzyme; ARB angiotensin-receptor blocker; HT
lan; UC  usual care.educe bed-days occupancy. Because this outcome is deter- tined partly by the duration of follow-up and by mortality,
fixed duration of follow-up was incorporated into the
efinition. After an interim analysis (see “Interim analysis”),
he duration of follow-up was reduced to 240 days. All-
ause mortality, symptoms, and optimization of medication
ere secondary outcomes. Investigators were asked to clas-
ify hospitalizations as due to heart failure, other cardiovas-
ular, or noncardiovascular. Deaths were classified as sud-
en, due to circulatory failure, or due to other causes.
ample size. We assumed that HTM would not alter
urvival, but we included a survival component in the
rimary end point because the number of days alive is a
ajor determinant of days in hospital. We estimated that
ortality would be 2% per month for the first 3 months,
.5% per month for the next 3 months, and 1% per month
hereafter (4). We assumed that the NTS groups would
pend an average of 10% of days-alive (41 days) in hospital
4) and that this would be reduced to 6% (25 days) by
TM. In other words, days lost to death or hospitalization
ould be reduced from 80 days to 63 days during 450 days
ollow-up, representing 17.8% and 14.0% of days exposure,
espectively. We also expected a highly skewed distribution
n the primary outcome, with approximately 25% of patients
n the control group surviving until the end of the study
ithout any hospital admission. Using a Wilcoxon (Mann-
hitney) rank-sum test, a study with 145 patients in each
f the two arms of primary interest was calculated to have
0% power to show significance at p  0.01 using a
wo-sided test. A total of 195 patients per arm would
rovide 90% power. The power calculations appeared robust
n (PMP)
Baseline
NTS HTM
%
reated
n
Treated
%
Treated
n
Treated
%
Treated
0.0% N/A 0.0% N/A 0.0%
100% 163 100% 160 100%
141 139
91% 137 97% 130 94%
17 8
50% 9 53% 2 25%
109 101
77% 86 79% 87 86%
114 101
74% 91 80% 81 80%
ed in 3-way comparison); ‡p  0.0007 for HTM vs. NTS; §p  0.0392 for HTM
(p  0.0354 for chi-squared in 3-way comparison); ¶data for evaluation closest to
Table 4, in which the data for 240 days precisely are shown.
home telemonitoring; NTS nurse telephone support; PMP patient managementt Pla
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wn ino a 10% to 20% rate of discontinuation of HTM. Accord-
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May 17, 2005:1654–64 The TEN-HMS Studyngly, we planned to assign 200 patients randomly to HTM,
00 to NTS, and 100 to UC.
tatistical analysis. Analyses were conducted by intention-
o-treat. Baseline characteristics were expressed as mean and
tandard deviation or median and interquartile range. Treat-
ent groups were compared using a two-sample Wilcoxon
est. Outcome measures were expressed as differences be-
ween means with 95% confidence intervals, calculated
sing the Scheffe’s multiple comparison procedure. Cate-
orical variables were analyzed using the chi-square test.
ontinuous outcome variables were not normally distrib-
ted and, therefore, the Kruskal-Wallis test was used.
For the survival distribution and statistical comparison,
he Kaplan-Meier estimation method with 95% confidence
evel for survivor function was used. An exploratory multi-
ariate Cox regression analysis was performed that included
he following covariates: assigned group, age, NT proBNP,
ody mass index, systolic and diastolic blood pressure,
emoglobin, sodium, urea, creatinine, NYHA functional
lassification, loop and potassium-sparing diuretics, ACE
nhibitors, and beta-blockers. Covariates were entered into
he model if the p value was 0.1. The final model was
nalyzed using the selected covariate and the variable
reatment group and applying Cox regression with stepwise
orward selection (entry p value 0.05).
Predefined subgroup analyses included age (lower two
erciles vs. upper tercile), gender, etiology of heart failure
ischemic heart disease vs. other), LV ejection fraction
lower two terciles vs. upper), dose of loop diuretic (40 mg
s.40 mg/day), and plasma concentration of NT-proBNP
120 Days Follow-Up¶
UC NTS HTM
n
Treated
%
Treated
n
Treated
%
Treated
n
Treated
%
Treated
13 18% 18 12% 13 9%
60 82% 134 88% 133 91%
54 118 121
42 78% 103 87% 116 96%*†
8 15 8
6 75% 10 67% 3 38%
47 91 90
34 72% 76 84% 84 93%‡§
38 97 85
27 71% 62 64% 69 81%lower tercile vs. upper two terciles). The statistical analysis Has conducted using the SAS System version 8.2 (SAS
nstitute, Cary, North Carolina).
nterim analysis. An interim analysis was conducted by the
ndependent statistical group (Institute for Medical Infor-
atics and Biostatistics) after 426 patients had been re-
ruited. They requested that recruitment of patients should
top and the trial brought to a close because of a large
ifference in mortality rates between the UC care group and
hose assigned randomly to NTS or HTM and because it
as unlikely that the primary end point would be reached.
fter examining the mortality data, the steering committee
greed to close the study to recruitment, inform the inves-
igators of the mortality difference, but continue follow-up
ntil October 2002 to allow an evaluation of days lost to
eath or hospitalization over the course of 240 days in
lmost all patients. This point became the revised primary
utcome measure.
ESULTS
etween August 2000 and March 2002, 426 patients were
ssigned randomly, of whom 4 were lost to follow-up and
2 declined to comply with regular telemonitoring over a
edian follow-up of 484 (interquartile range, 317 to 622)
ays (Fig. 2). A total of 81% of patients assigned randomly
o HTM had 80% compliance with at least one daily
easurement (weight or blood pressure), and 55% had
80% compliance with twice daily measurements. A total
f 296 patients died or had at least one day in hospital. Four
atients had 240 days of follow-up (2 in NTS and 2 in
240 Days Follow-Up¶
UC NTS HTM
n
reated
%
Treated
n
Treated
%
Treated
n
Treated
%
Treated
19 26% 27 18% 27 18%
55 74% 125 82% 120 82%
50 112 109
40 80% 98 88% 93 85%
7 15 8
4 57% 8 53% 4 50%
44 84 82
34 77% 74 88% 75 92%
36 93 79
27 75% 66 71% 63 80%TTM).
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The TEN-HMS Study May 17, 2005:1654–64The baseline characteristics of this population and the
umbers assigned to each group are shown in Tables 1 to 3.
he median duration of heart failure was 2.2 (range 0.2 to
.2) years and, excluding the index admission, patients had
ad an average of two heart failure-related admissions in the
revious year. Most patients had experienced an episode of
YHA class IV heart failure in the previous month (Table
), although 62% reported well-controlled symptoms
NYHA functional class I/II) at the time of assignment.
owever, other variables indicated a poor prognosis (16).
or instance, 48% of patients were aged70 years, ischemic
eart disease was common, LV ejection fraction was se-
erely depressed, mean systolic blood pressure was low, and
iuretic doses, mean serum creatinine, and plasma NT-
roBNP were high. Patients were managed intensively even
efore randomization (Table 3).
Over the course of 240 days, fewer days were lost to death
r hospitalization among patients who were assigned ran-
omly to HTM compared with NTS, but this number did
ot achieve statistical significance (Table 4). A total of 71%
f hospitalizations were cardiovascular (262 of 368) but only
0% (147) were related to heart failure. Home telemonitor-
ng was associated with a trend to more hospital admissions
ith heart failure but a significant reduction in the average
uration of admissions compared with NTS. Overall, there
as a trend to a reduction in days in hospital with HTM
ompared with NTS (10.9 days vs. 14.8 days). Home
elemonitoring reduced days in hospital for heart failure and
or other causes similarly. Patients assigned to UC fared
orst, predominantly because of poorer survival. A total of
71 patients (64%) were followed for 450 days. No signif-
cant differences were observed between HTM and NTS at
able 4. Primary Outcome Measure and its Components at 240-
240-Day Follow-Up UC NTS
umber of patients 85 170
otential days 19,974 40,192
atients hospitalized 46 (54%) 85 (49%)
umber of hospitalizations 69 144
ays in hospital 813 (4.1%) 2,514 (6.3%)
uration per admission
(median IQR)
7 (4 to 12) 12 (5 to 21)
atients hospitalized for heart failure 24 (28%) 34 (20%)
eart failure hospitalizations 33 47
ther cardiovascular hospitalizations 23 58
oncardiovascular hospitalizations 13 39
ays in hospital for heart failure 512 (2.6%) 1115 (2.8%)
uration per heart failure admission
(median IQR)
11 (6 to 20) 15 (7 to 29)
eaths 20 (24%) 27 (16%)
irculatory failure 14 21
udden death 4 5
ther 2 1
ays lost due to death 3,072 (15.4%) 3,875 (9.6%)
atients dead or with at least one
hospitalization
48 (56%) 92 (54%)
ays dead or hospitalized 3,885 (19.5%) 6,389 (15.9%)
TM  home telemonitoring; IQR  interquartile range; NTS  nurse telephone50 days in primary or secondary outcomes (Table 5). compared with those in UC, patients assigned to HTM or
TS had a significantly lower rate of mortality and conse-
uently lost fewer days to death or hospitalization.
The study was not adequately powered for a robust
ubgroup analysis. Exploratory analyses did not identify any
pecific subgroup that obtained significantly greater benefit
rom HTM compared with NTS for the primary end point.
atients assigned randomly to receive UC had a significantly
igher all-cause mortality than patients assigned to NTS
r HTM (Fig. 3). Variables carrying independent prog-
ostic value in the multiple covariate Cox regression
nalysis are shown in Tables 6 and 7. In this model,
ncrements in NT-proBNP (per tercile) had the strongest
ssociation with adverse outcome (Fig. 4), whereas as-
ignment to receive UC was independently associated
ith an adverse prognosis.
The NYHA functional class was similar among surviving
atients in the three groups at 120 days and 240 days (Table 2).
t 120 days, patients assigned randomly to receive HTM were
ore likely to receive ACE inhibitors, beta-blockers, and
pironolactone according to their management plan than those
ssigned to NTS and more likely to receive ACE inhibitors
nd beta-blockers than those assigned to UC (Table 3). No
ignificant differences were found between NTS and UC with
egards to the uptake of treatment. By 240 days, these
ifferences were no longer significant.
Data on patient contacts other than hospitalization were
ollected by monthly review in the NTS and HTM groups
ut only every four months in the UC group (Table 8). This
ifference may have led to under-reporting of contacts in the
atter group. The NTS and HTM groups were associated
ith a substantial and similar increase in reported patient-
Follow-Up
TM HTM vs. NTS HTM vs. UC NTS vs. UC
163 Difference between means and 95% confidence interval
,539 Not analyzed
(47%) Not analyzed
155 Not analyzed
(4.6%) 4 (10 to 2) 1 (9 to 6) 5 (2 to 13)
to 15) 6 (11 to 1) 0 (7 to 6) 6 (1 to 12)
(25%) Not analyzed
67 Not analyzed
42 Not analyzed
46 Not analyzed
(2.5%) 1 (5 to 4) 0 (5 to 5) 1 (6 to 5)
6 to 19) 9 (20 to 2) 1 (13 to 11) 8 (5 to 21)
(17%) Not analyzed
17 Not analyzed
9 Not analyzed
2 Not analyzed
(8.1%) 4 (20 to 12) 17 (36 to 2) 13 (33 to 6)
(51%) Not analyzed
(12.7%) 8 (25 to 10) 16 (37 to 6) 8 (29 to 13)
rt; UC  usual care.Day
H
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May 17, 2005:1654–64 The TEN-HMS Studynd telephone contacts, compared with UC. The overall
umber of contacts also was significantly greater with NTS
han HTM during 450 days of follow-up. There was a
ubstantial substitution of home and office visits with
elephone contacts with HTM compared with NTS.
ISCUSSION
his study strongly suggests that HTM or a nurse-based
eart failure service, using more conventional telephone
upport (i.e., NTS) can reduce mortality substantially in
atients with heart failure and LV systolic dysfunction who
ave recurrent heart failure admissions. The reduction in
ortality is achieved without an increase in the duration of
ime spent in hospital. Compared with NTS, HTM re-
igure 3. Mortality in each of the randomized groups. A difference was
ound between usual care and either nurse telephone support or home
elemonitoring (chi-squared test: p  0.0397). The absolute difference in
able 5. Primary Outcome Measure and its Components at 450-
450-Day Follow-Up UC NTS
umber of patients 55 110
otential days 24,750 49,500
atients hospitalized 40 (73%) 73 (66%)
umber of hospitalizations 85 151
ays in hospital 1,017 (4.1%) 2,423 (4.9%)
uration per admission
(median IQR)
7 (4 to 13) 9 (4 to 19)
atients hospitalised for heart failure 23 (42%) 32 (29%)
eart failure hospitalizations 36 49
ther cardiovascular hospitalizations 32 62
on-cardiovascular hospitalisations 17 40
ays in hospital for heart failure 597 (2.4%) 1,163 (2.3%)
uration per heart failure admission
(median IQR)
11 (6 to 21) 12 (7 to 21)
eaths 28 (51%) 34 (31%)
irculatory failure 18 26
udden death 7 6
ther 3 2
ays lost due to death 8,137 (32.9%) 8,116 (16.4%)
atients dead or with at least one
hospitalization
47 (85%) 79 (72%)
ays dead or hospitalized 9,154 (37.0%) 10,539 (21.3%) 1
TM  home telemonitoring; IQR  interquartile range; NTS  nurse telephoner
ortality at one year was 16% to 18%. Dashed line  usual care; dotted
ine  nurse support; solid line  telemonitoring.uced the duration of hospital admissions and the number
f home or office visits substantially. The combined benefits
n mortality and consumption of health care resource
uggest that HTM may have an important role in the
anagement of heart failure. Although the primary hypoth-
sis was not proved, this study suggests that HTM may be
he most cost-effective solution for the delivery of expert
are for patients with heart failure.
Most patients in this trial reported few or no symptoms at
he time of assignment despite severe cardiac dysfunction,
hich may reflect the ability of intensive therapy to control
ymptoms. Alternatively, the assessment of symptoms in the
ftermath of an episode of severe decompensation may be
nreliable, either because of the patient’s perception that
ymptoms have improved or because the patient has not yet
ried to return to his or her usual activities. Mortality and
ecurrent hospitalization rates were high, indicating that a
imple assessment of symptoms at discharge is not an
dequate guide to prognosis. The severity of LV systolic
ysfunction, high rates of comorbidity, significant renal
ysfunction, and low arterial pressure all predicted a poor
rognosis (16). In addition, the median plasma concentra-
ion of NT-proBNP was markedly elevated and similar to
hat reported in studies of severe persistent heart failure
17). This study not only emphasizes that patients with
evere cardiac dysfunction and a poor prognosis may have
nly intermittently severe symptoms but also shows that
utcome can be modified if a high standard of care is
rovided.
Days lost to death or hospitalization, the primary out-
ome measure in this study, is a relatively novel but highly
Follow-Up
TM HTM vs. NTS HTM vs. UC NTS vs. UC
106 Difference between means and 95% confidence interval
,700 Not analyzed
(71%) Not analyzed
159 Not analyzed
(4.0%) 4 (15 to 6) 0 (13 to 13) 4 (9 to 16)
to 16) 4 (10 to 2) 0 (7 to 7) 4 (3 to 11)
(36%) Not analyzed
71 Not analyzed
52 Not analyzed
36 Not analyzed
(1.9%) 2 (11 to 7) 2 (13 to 9) 0 (11 to 11)
to 18) 11 (24 to 2) 4 (18 to 10) 7 (8 to 22)
(34%) Not analyzed
24 Not analyzed
9 Not analyzed
3 Not analyzed
(18.5%) 10 (38 to 57) 65 (6 to 123) 74 (16 to 132)
(76%) Not analyzed
(22.6%) 6 (44 to 56) 65 (4 to 125) 71 (10 to 131)
rt; UC  usual care.Day
H
47
75
1,925
9 (5
38
912
9 (6
36
8,841
81
0,766elevant outcome in clinical and health economic terms.
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The TEN-HMS Study May 17, 2005:1654–64aplan-Meier (time-to-first-event) curves are an accurate
ethod for displaying the effects of treatment on mortality
ut may be misleading for nonfatal events (18). In “time-
o-first-event” analyses for a composite of fatal and nonfatal
vents, a minor event has the same value as death, and a
atient who has a single, short, early admission is ascribed a
orse outcome than one who has multiple later, long-term
dmissions. Hospitalization, especially when brief, may
eflect early detection of problems and good care rather than
n adverse outcome. Days lost to death or hospitalization,
ssuming all patients are followed for a similar time,
ombines mortality with a more sensible measure of mor-
idity; the number of days spent in hospital.
There are several reasons why increased monitoring by
urses or telemonitoring might improve outcome in this
opulation. Better organization of care and patient support
ight increase the likelihood of patients being initiated and
aintained on appropriate treatment for heart failure. This
ypothesis was confirmed for HTM but not for NTS.
arlier detection of cardiovascular and noncardiovascular
roblems by well-organized care also may have led to more
rompt and effective therapy for a variety of problems, both
ardiovascular and noncardiovascular.
Two recent reports support the notion that telemonitor-
ng may improve mortality in patients with heart failure.
he Weight Monitoring in Heart Failure (WHARF) trial
eported a 10.4% absolute and 56.2% relative reduction in
ortality during an average follow-up of 169 days in 280
atients with a HTM system for symptoms and weight
ompared with UC (14). In one of the largest trials of
isease management for heart failure, a 5% absolute and
able 6. Results of Multivariate Cox Regression Analysis
Variable DF
Analysis of Maximum
Parameter
Estimate
Standard
Error C
andom 1 0.28824 0.14016
ge 1 0.04734 0.01173
NP, tercile 1 0.50148 0.14546
MI 1 0.08069 0.02871
iastolic BP 1 0.02242 0.00946
emoglobin (g/dl) 1 0.14745 0.05647
odium 1 0.04641 0.02335
reatinine class 1 0.32216 0.15594
Serum creatinine 120 mol/l, 120 to 200 mol/l, or  200 mol/l.
BMI  body mass index; BNP  brain natriuretic peptide; BP  blood pressur
able 7. Summary of Forward Selection
Step Variable Entered
Number
In
Score
Chi-Square
Pr >
Chi-Square
1 BNP, tercile 2 32.6540 0.0001
2 Age 3 21.2488 0.0001
3 Sodium 4 9.2459 0.0024
4 Hemoglobin (g/dl) 5 7.1722 0.0074
5 BMI 6 6.5690 0.0104
6 Diastolic BP 7 5.7513 0.0165
7 Creatinine class 8 4.2956 0.0382p
tMI  body mass index; BNP  brain natriuretic peptide, BP  blood pressure.8% relative reduction in mortality was reported with NTS
ompared with UC among patients with heart failure due to
V systolic dysfunction but not those without systolic
ysfunction (12). The fact that benefit occurred only in the
roup of patients in whom pharmacologic interventions
ave been shown to reduced mortality provides supportive
vidence that this response was rather specific to the
anagement program and not just a general response to
mproved care. However, neither study showed a reduction
n hospitalizations or other healthcare use. Perhaps it is time
o move away from always imputing an adverse outcome to
ealthcare contacts or hospitalizations in trials and service
udits. If such events improve how patients feel and reduce
heir mortality then, provided they are affordable, they
hould be welcomed, especially when they prevent rather
han respond to crises.
Patients assigned randomly to NTS spent the highest
roportion of days in hospital, which appears to reflect, on
he one hand, the high mortality rate in the UC group,
ecause death prevents hospitalization and, on the other
and, a reduction in hospital days with HTM. The reasons
or the reduction in days spent in hospital by HTM appear
omplex. Patients were more likely to be hospitalized with
eart failure in this group, perhaps reflecting the early
igure 4. Overall mortality for patients with patients in the lowest (tercile
: 1,742 pg/ml), mid- (tercile 2: 1,743 to 5,210 pg/ml), and highest
tercile 3: 5,211 pg/ml) tercile of N-terminal pro-brain natriuretic
lihood Estimates
Hazard
Ratio
95% Hazard
Ratio Confidence
Limitsquare Pr > Chi-Square
290 0.0397 0.750 0.570 0.987
939 0.0001 1.048 1.025 1.073
847 0.0006 1.651 1.242 2.196
982 0.0049 0.922 0.872 0.976
145 0.0178 0.978 0.960 0.996
174 0.0090 0.863 0.772 0.964
502 0.0469 0.955 0.912 0.999
680 0.0388 1.380 1.017 1.873
 degrees of freedom.Like
hi-S
4.2
16.2
11.8
7.8
5.6
6.8
3.9
4.2eptide; p  0.0006 (chi-squared test) for the difference. Dotted line 
ercile 1; dashed line  tercile 2; solid line  tercile 3.
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May 17, 2005:1654–64 The TEN-HMS Studyetection of deterioration and possibly some false alarms.
owever, hospital stays were shorter for patients assigned to
TM, which may reflect improved planning of both ad-
issions and discharges so that effective care was delivered
uickly by appropriately trained staff. In addition, there may
ave been a greater willingness to discharge a patient
nowing that monitoring and titration of therapy could be
acilitated at home. In this context, it could be argued that
any of these hospitalizations were appropriate, contrib-
ted to the continued well-being of the patient, and that
TM was encouraging a more flexible and dynamic use of
greater spectrum of resources appropriate to patients’
eeds.
Improved access to care, either by nurses or by telemoni-
oring, appeared to lead to an increase in patient contacts,
hich is not surprising. Home visits are potentially an
xpensive method of delivering health care because the
ealth care professional may spend considerable time trav-
ling to and from the patients home, although visiting the
able 8. Patient Contacts Not Resulting in Hospitalization
240 Days
UC* NTS
umber of patients 85 170
otal days at risk† 16,089 33,803
mergency room visits
Visits 8 54
Total/1,000 days at
risk (95% CI)
0.5 (0.2 to 0.8) 1.6 (1.2 to 2.0) 1.8
ffice visits
Family practitioner 119 602
Specialist 34 117
Nurse and other 36 104
Total 189 823
Total/1,000 days at
risk (95% CI)
11.7 (10.1 to 13.4) 24.3 (22.7 to 26.0) 19.4
ome visits
Family practitioner 42 185
Specialist 0 3
Nurse and other 27 206
Total 69 394
Total/1,000 days at
risk (95% CI)
4.3 (3.3 to 5.9) 11.7 (10.5 to 12.8) 8.7
ll face-to-face
patient contacts
Total 300 1,388
Total/1,000 days at
risk (95% CI)
18.6 (16.6 to 20.7) 41.1 (38.9 to 43.2) 33.1
elephone calls
Total 90 914
Total/1,000 days at
risk (95% CI)
5.6 (4.4 to 6.8) 27.0 (25.3 to 28.8) 35.1
ll patient contacts
Total contacts 390 2,302
Total/1,000 days at
risk (95% CI)
24.2 (21.9 to 26.6) 68.1 (65.4 to 70.8) 68.2
Note that patient contacts were evaluated only once every four months in the usu
nder-reporting of contacts. †Days at risk means days-alive and out of hospital.
CI  confidence interval; HTM  home telemonitoring; NTS  nurse telephoatient in his or her home environment may help ensure That the patient is complying with medication and coping
ith his or her situation (8). Office visits make fewer
emands on the healthcare professional’s time but more
emands on the patient, including time and travel costs. By
omparison, telephone calls are an inexpensive way of
aking healthcare contacts. In the context of the
EN-HMS study, substituting a large proportion of face-
o-face contacts with telephone calls does not appear to have
n adverse effect on the uptake of therapy, symptoms,
ospitalization, survival, or patient satisfaction when sup-
orted by telemonitoring.
Although many patients were elderly, their acceptance
nd ability to cope with the HTM technology was high.
ew patients asked for the equipment to be removed or
ailed to comply with daily measurements. Good or very
ood satisfaction with HTM was reported by 96% of
atients.
This trial is one of the first substantial, prospective,
andomized ones for HTM for patients with heart failure.
450 Days
UC# NTS HTM
63 55 110 106
41 15,596 38,961 36,934
60 13 60 67
to 2.2) 0.8 (0.4 to 1.3) 1.5 (1.2 to 1.9) 1.8 (1.4 to 2.3)
54 103 591 504
00 46 139 133
00 36 113 118
54 185 843 755
to 20.9) 11.9 (10.2 to 13.6) 21.6 (20.2 to 23.1) 20.4 (19.0 to 21.9)
62 25 192 140
1 0 3 3
28 19 488 94
91 44 683 237
to 9.6) 2.8 (2.0 to 3.7) 17.5 (16.2 to 18.8) 6.4 (5.6 to 7.2)
15 242 1,586 1,059
to 35.1) 15.5 (13.6 to 17.5) 40.7 (38.7 to 42.7) 28.7 (29.7 to 33.2)
80 102 1,020 1,161
to 37.0) 6.5 (5.2 to 7.8) 26.2 (24.6 to 27.8) 31.4 (29.7 to 33.2)
95 344 2,606 2,220
to 70.9) 22.1 (19.8 to 29.4) 66.9 (64.4 to 69.9) 60.1 (57.7 to 62.5)
e group compared with monthly in the other two groups, which may have led to
port; UC  usual care.HTM
1
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The TEN-HMS Study May 17, 2005:1654–64ervice development and further research. Improved selec-
ion of patients and tailoring the duration of HTM to the
atient’s needs could enhance the benefits and lower the
osts of therapy further. There was little practical expe-
ience of HTM for heart failure when this study was
lanned, and nurses and medical staff had to learn how to
se the technology as the study progressed. Staff training
rograms based on this study also could improve the
ffectiveness of HTM. Finally, improvements in devices,
ommunication, and data processing for decision support
ll are likely to increase the potential of HTM to benefit
atients.
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